Development a novel in silico mRNA vaccine against Clostridium difficile

Clostridium difficile, a toxin-producing bacterium, can lead to conditions ranging from mild diarrhea to severe pseudomembranous colitis. Our research introduces an innovative strategy for developing a multi-epitope mRNA vaccine using in-silico methods targeting proteins involved in Clostridium difficile infection (CDI). Through computational models, we identified epitopes for B cells, helper T lymphocytes (HTL), and cytotoxic T lymphocytes (CTL) from protein sequences, assessing their immune response potential, allergenicity, toxicity, and autoimmune risk. The constructed 3D model underwent interaction docking and immune simulations, including evaluations of population coverage and physicochemical properties. Finally, molecular dynamics simulations were employed to test the vaccine's stability. Our findings suggest that this approach holds promise for creating a multi-epitope mRNA vaccine against C. difficile infection.